How Nicotine Withdrawal Alters Neuropeptide Y Signaling in the Brain

Nicotine withdrawal significantly increases neuropeptide Y (NPY) and its receptor expression in brain reward circuits, potentially representing a compensatory mechanism against withdrawal-induced negative mood states.

Birdogan, Ali et al.·Neuropeptides·2021·Preliminary Evidenceanimal
RPEP-05285AnimalPreliminary Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
animal
Evidence
Preliminary Evidence
Sample
N=not reported
Participants
Rats given chronic oral nicotine for 12 weeks

What This Study Found

Nicotine withdrawal (24-48h) dramatically increased NPY and receptor (Y1, Y2, Y5) mRNA levels across the mesocorticolimbic system, suggesting NPY signaling upregulation as a compensatory response to withdrawal-induced negative affect.

Key Numbers

12 weeks nicotine; 25-50 mcg/mL dose; 24h and 48h withdrawal; NPY, Y1, Y2, Y5 mRNA increased

How They Did This

Rats received oral nicotine (25-50 μg/ml) in drinking water for 12 weeks, then were withdrawn for 0, 24, or 48 hours. Brain NPY and receptor mRNA measured by qRT-PCR. Somatic withdrawal signs and locomotor activity assessed.

Why This Research Matters

Understanding the neurochemical changes during nicotine withdrawal could help develop better smoking cessation therapies, particularly ones targeting the NPY system to reduce withdrawal-associated anxiety and depression.

The Bigger Picture

Nicotine addiction affects hundreds of millions worldwide, and withdrawal symptoms are a major barrier to quitting. This study identifies the NPY system as a key player in withdrawal-induced negative mood states, opening potential therapeutic avenues for smoking cessation beyond current nicotine replacement approaches.

What This Study Doesn't Tell Us

Animal study using oral nicotine delivery, which differs from smoking. mRNA levels may not directly reflect peptide or protein levels. Limited to male rats in the study design details provided.

Questions This Raises

  • ?Could NPY-targeting drugs reduce nicotine withdrawal symptoms and improve cessation rates?
  • ?Is the NPY response protective against withdrawal-induced anxiety, or does it contribute to it?
  • ?Do similar NPY changes occur in human smokers during withdrawal?

Trust & Context

Key Stat:
Widespread NPY upregulation at 24-48h withdrawal Across amygdala, nucleus accumbens, and prefrontal cortex — key mood and reward brain regions
Evidence Grade:
Well-controlled animal study with multiple time points and brain regions analyzed using quantitative PCR. Pre-clinical evidence.
Study Age:
Published in 2021, contributing to understanding of neuropeptide involvement in addiction and withdrawal.
Original Title:
Chronic oral nicotine administration and withdrawal regulate the expression of neuropeptide Y and its receptors in the mesocorticolimbic system.
Published In:
Neuropeptides, 90, 102184 (2021)
Database ID:
RPEP-05285

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is neuropeptide Y and why does it matter for quitting smoking?

Neuropeptide Y (NPY) is a brain chemical that regulates mood, stress, and anxiety. During nicotine withdrawal, NPY levels increase dramatically in brain areas controlling emotions and reward, potentially as the brain's attempt to cope with the negative feelings that make quitting so difficult.

Could this research lead to better quit-smoking treatments?

Potentially. By identifying the NPY system as actively involved in nicotine withdrawal, researchers could develop drugs that modulate NPY signaling to reduce withdrawal symptoms like anxiety and depression, making it easier to quit smoking.

Read More on RethinkPeptides

Cite This Study

RPEP-05285·https://rethinkpeptides.com/research/RPEP-05285

APA

Birdogan, Ali; Salur, Elif; Tuzcu, Fulya; Gokmen, Ramazan C; Ozturk Bintepe, Meliha; Aypar, Buket; Keser, Aysegul; Balkan, Burcu; Koylu, Ersin O; Kanit, Lutfiye; Gozen, Oguz. (2021). Chronic oral nicotine administration and withdrawal regulate the expression of neuropeptide Y and its receptors in the mesocorticolimbic system.. Neuropeptides, 90, 102184. https://doi.org/10.1016/j.npep.2021.102184

MLA

Birdogan, Ali, et al. "Chronic oral nicotine administration and withdrawal regulate the expression of neuropeptide Y and its receptors in the mesocorticolimbic system.." Neuropeptides, 2021. https://doi.org/10.1016/j.npep.2021.102184

RethinkPeptides

RethinkPeptides Research Database. "Chronic oral nicotine administration and withdrawal regulate..." RPEP-05285. Retrieved from https://rethinkpeptides.com/research/birdogan-2021-chronic-oral-nicotine-administration

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.